 Connection
Martin McCarter to Adolescent
This is a "connection" page, showing publications Martin McCarter has written about Adolescent.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.240 |
|
|
|
-
Stewart CL, Gleisner A, Halpern A, Ibrahim-Zada I, Luna RA, Pearlman N, Gajdos C, Edil B, McCarter M. Implications of Hyperthermic Intraperitoneal Chemotherapy Perfusion-Related Hyperglycemia. Ann Surg Oncol. 2018 Mar; 25(3):655-659.
Score: 0.042
-
Jones TS, Jones EL, Gao D, Pearlman NW, Robinson WA, McCarter M. Management of external ear melanoma: the same or something different? Am J Surg. 2013 Sep; 206(3):307-13.
Score: 0.031
-
McCarter MD, Antonescu CR, Ballman KV, Maki RG, Pisters PW, Demetri GD, Blanke CD, von Mehren M, Brennan MF, McCall L, Ota DM, DeMatteo RP. Microscopically positive margins for primary gastrointestinal stromal tumors: analysis of risk factors and tumor recurrence. J Am Coll Surg. 2012 Jul; 215(1):53-9; discussion 59-60.
Score: 0.029
-
Kounalakis N, Gao D, Gonzalez R, Becker M, Lewis K, Poust J, Pearlman N, Robinson W, McCarter M. A neoadjuvant biochemotherapy approach to stage III melanoma: analysis of surgical outcomes. Immunotherapy. 2012 Jul; 4(7):679-86.
Score: 0.029
-
Roaten JB, Partrick DA, Bensard D, Pearlman N, Gonzalez R, Fitzpatrick J, McCarter MD. Survival in sentinel lymph node-positive pediatric melanoma. J Pediatr Surg. 2005 Jun; 40(6):988-92; discussion 992.
Score: 0.018
-
Roaten JB, Partrick DA, Pearlman N, Gonzalez RJ, Gonzalez R, McCarter MD. Sentinel lymph node biopsy for melanoma and other melanocytic tumors in adolescents. J Pediatr Surg. 2005 Jan; 40(1):232-5.
Score: 0.017
-
Dillon SM, Liu J, Purba CM, Christians AJ, Kibbie JJ, Castleman MJ, McCarter MD, Wilson CC. Age-related alterations in human gut CD4 T cell phenotype, T helper cell frequencies, and functional responses to enteric bacteria. J Leukoc Biol. 2020 01; 107(1):119-132.
Score: 0.012
-
Li SX, Sen S, Schneider JM, Xiong KN, Nusbacher NM, Moreno-Huizar N, Shaffer M, Armstrong AJS, Severs E, Kuhn K, Neff CP, McCarter M, Campbell T, Lozupone CA, Palmer BE. Gut microbiota from high-risk men who have sex with men drive immune activation in gnotobiotic mice and in vitro HIV infection. PLoS Pathog. 2019 04; 15(4):e1007611.
Score: 0.012
-
Trinh BB, Chapman BC, Gleisner A, Kwak JJ, Morgan R, McCarter MD, Gajdos C, Kounalakis N. SPECT/CT Adds Distinct Lymph Node Basins and Influences Radiologic Findings and Surgical Approach for Sentinel Lymph Node Biopsy in Head and Neck Melanoma. Ann Surg Oncol. 2018 Jun; 25(6):1716-1722.
Score: 0.011
-
Corless CL, Ballman KV, Antonescu CR, Kolesnikova V, Maki RG, Pisters PW, Blackstein ME, Blanke CD, Demetri GD, Heinrich MC, von Mehren M, Patel S, McCarter MD, Owzar K, DeMatteo RP. Pathologic and molecular features correlate with long-term outcome after adjuvant therapy of resected primary GI stromal tumor: the ACOSOG Z9001 trial. J Clin Oncol. 2014 May 20; 32(15):1563-70.
Score: 0.008
-
DeMatteo RP, Ballman KV, Antonescu CR, Corless C, Kolesnikova V, von Mehren M, McCarter MD, Norton J, Maki RG, Pisters PW, Demetri GD, Brennan MF, Owzar K. Long-term results of adjuvant imatinib mesylate in localized, high-risk, primary gastrointestinal stromal tumor: ACOSOG Z9000 (Alliance) intergroup phase 2 trial. Ann Surg. 2013 Sep; 258(3):422-9.
Score: 0.008
-
Gajdos C, Hawn MT, Kile D, Henderson WG, Robinson T, McCarter M, Nehler M. The risk of major elective vascular surgical procedures in patients with end-stage renal disease. Ann Surg. 2013 Apr; 257(4):766-73.
Score: 0.008
-
Dematteo RP, Ballman KV, Antonescu CR, Maki RG, Pisters PW, Demetri GD, Blackstein ME, Blanke CD, von Mehren M, Brennan MF, Patel S, McCarter MD, Polikoff JA, Tan BR, Owzar K. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet. 2009 Mar 28; 373(9669):1097-104.
Score: 0.006
-
Pearlman NW, McCarter MD, Frank M, Hurtubis C, Merkow RP, Franklin WA, Gonzalez R, Lewis K, Roaten JB, Robinson WA. Size of sentinel node metastases predicts other nodal disease and survival in malignant melanoma. Am J Surg. 2006 Dec; 192(6):878-81.
Score: 0.005
-
Lewis KD, Robinson WA, McCarter M, Pearlman N, O'Day SJ, Anderson C, Amatruda TT, Baron A, Zeng C, Becker M, Dollarhide S, Matijevich K, Gonzalez R. Phase II multicenter study of neoadjuvant biochemotherapy for patients with stage III malignant melanoma. J Clin Oncol. 2006 Jul 01; 24(19):3157-63.
Score: 0.005
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|